problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl13222problendo-13222Research ArticleКлиническая эндокринологияClinical endocrinologyСовременные представления о генетических и иммуногистохимических особенностях пролактин-секретирующих аденом гипофизаModern concepts of genetic and immunohistochemical features of prolactin-secreting pituitary adenomashttps://orcid.org/0000-0003-0047-7223ШутоваА. С.ShutovaA. S.

Шутова Александра Сергеевна.

Москва, ул. Дмитрия Ульянова, д. 11, 117036

Aleksandra S. Shutova.

Dmitry Ulyanov street, 11, Moscow 117036

shutova.aleksandra@gmail.comhttps://orcid.org/0000-0002-0327-4619ДзерановаЛ. К.DzeranovaL. K.

Дзеранова Лариса Константиновна – доктор медицинских наук.

Москва

Larisa K. Dzeranova - MD, PhD.

Moscow

dzeranovalk@yandex.ruВоротниковаС. Ю.VorotnikovaS. Yu.

Воротникова Светлана Юрьевна – кандидат медицинских наук.

Москва

Svetlana Yu. Vorotnikovа.

Moscow

vorotnikova.s.y@gmail.comhttps://orcid.org/0000-0002-6520-4296КутинМ. A.KutinM. A.

Кутин Максим Александрович - кандидат медицинских наук.

Москва

Maxim A. Kutin – PhD.

Moscow

dr.m.kutin@yandex.ruhttps://orcid.org/0000-0001-6539-466XПигароваЕ. А.PigarovaE. A.

Пигарова Екатерина Александровна - доктор медицинских наук.

Москва

Ekaterina A. Pigarova - MD, Phd.

Moscow

kpigarova@gmail.comНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian FederationНациональный медицинский исследовательский центр нейрохирургии имени академика Н.Н. БурденкоРоссияN.N. Burdenko National Medical Research Center of NeurosurgeryRussian Federation2023300620236934450Copyright © Шутова А.С., Дзеранова Л.К., Воротникова С.Ю., Кутин М.A., Пигарова Е.А., 20232023Шутова А.С., Дзеранова Л.К., Воротникова С.Ю., Кутин М.A., Пигарова Е.А.Shutova A.S., Dzeranova L.K., Vorotnikova S.Y., Kutin M.A., Pigarova E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/13222

Пролактиномы — наиболее распространенные гормонально-активные аденомы гипофиза. В 20% случаев наблюдается резистентность к методу выбора их лечения — медикаментозной терапии агонистами дофамина. Наличие резистентности обусловливает прогрессию патологических проявлений гиперпролактинемии и негативные топографо-анатомические изменения пролактиномы. Причины нечувствительности к терапии агонистами дофамина не вполне изучены, а подходы к ведению пациентов требуют уточнения. Существующие в настоящее время концепции резистентности базируются на данных, получаемых в результате оперативного вмешательства или после периода длительной неэффективной терапии. В связи с этим весьма актуален поиск методов оценки чувствительности пролактин-секретирующих аденом к медикаментозной терапии на раннем диагностическом этапе. Особое место среди этих методов занимают молекулярно-генетические исследования, позволяющие прогнозировать ответ аденомы на медикаментозную терапию до проведения хирургического лечения. На основании полученных данных возможно формирование персонализированного алгоритма ведения пациентов.

Prolactinomas are the most common secreting adenomas of the pituitary. In 20% of cases resistance to dopamine-agonists treatment is observed. Medical therapy resistance causes progression of pathological symptoms of hyperprolactinemia and negative topographic and anatomical changes of prolactinoma. The causes of ineffectiveness of dopamine agonists therapy are not fully understood as well as approaches to managing patients require clarification. Current concepts of resistance are based on the data obtained as a result of surgery or after a period of long-term ineffective therapy. Thus, it is very important to find methods of assessing the sensitivity of prolactin-secreting adenomas to drug therapy before surgical treatment. Genetic and immunohistochemical studies find special place among these methods, making it possible to predict adenoma’s response to drug therapy at early diagnostic stage. Obtained results will allow us to form personalized algorithm for managing patients.

аденомы гипофизапролактиномырезистентность к терапиииммуногистохимическое исследованиегенетическое исследованиеpituitary adenomasprolactinomasresistance to therapyimmunohistochemical studygenetic studyDaly Adrian F. Beckers Albert The Epidemiology of Pituitary Adenomas Endocrinology and Metabolism Clinics of North America 2020 06 347 355 49 3 10.1016/j.ecl.2020.04.002Molitch Mark E. Diagnosis and Treatment of Pituitary Adenomas JAMA 2017 02 516 317 5 10.1001/jama.2016.19699Fedorova N. S. Abrosimov A. Yu. Dzeranova L. K. Pigarova E. A. Dedov I. I. Pituitary lactotroph adenomas resistant to dopamine agonist treatment: histological and immunohistochemical characteristics Arkhiv patologii 2018 06 34 80 3 10.17116/patol201880334-39Maiter Dominique Management of Dopamine Agonist-Resistant Prolactinoma Neuroendocrinology 2018 11 42 50 109 1 10.1159/000495775Donoho Daniel A. Laws Edward R. The Role of Surgery in the Management of Prolactinomas Neurosurgery Clinics of North America 2019 07 509 514 30 4 10.1016/j.nec.2019.05.010Astafyeva Ludmila I. Kadashev Boris A. Kalinin Pavel L. Kutin Maxim A. Sidneva Yuliya G. Ismailov Denilbek B. Chernov Ilya V. Yatsenko Dina A. Dzeranova Larisa K. Cerebrospinal fluid rhinorrhoea in young women after 6.5 years of therapy giant prolactinoma with Cabergolin Endocrine Surgery 2018 03 201 208 11 4 10.14341/serg9485Wong Anni Eloy Jean Anderson Couldwell William T. Liu James K. Update on prolactinomas. Part 2: Treatment and management strategies Journal of Clinical Neuroscience 2015 08 1568 1574 22 10 10.1016/j.jocn.2015.03.059Di Sarno Antonella Landi Maria Luisa Cappabianca Paolo Di Salle Francesco Rossi Francesca W. Pivonello Rosario Di Somma Carolina Faggiano Antongiulio Lombardi Gaetano Colao Annamaria Resistance to Cabergoline as Compared with Bromocriptine in Hyperprolactinemia: Prevalence, Clinical Definition, and Therapeutic Strategy The Journal of Clinical Endocrinology & Metabolism 2014 01 5256 5261 86 11 10.1210/jcem.86.11.8054Valea Ana Sandru Florica Petca Aida Dumitrascu Mihai Carsote Mara Petca Razvan-Cosmin Ghemigian Adina Aggressive prolactinoma (Review) Experimental and Therapeutic Medicine 2021 11 23 1 10.3892/etm.2021.10997Caccavelli L. Morange-Ramos I. Kordon C. Jaquet P. Enjalbert A. Alteration of Gα Subunits mRNA Levels in Bromocriptine Resistant Prolactinomas Journal of Neuroendocrinology 2003 11 737 746 8 10 10.1046/j.1365-2826.1996.04902.xTamagno G, Gahete MD. Pituitary Adenomas: The European Neuroendocrine Association’s Young Researcher Committee Overview Murray JF. LTP. Anterior pituitary: somatotrophs (GH) and lactotrophs (PRL). In: Litwack G, editor. Hormonal Signaling in biology and medicine: comprehensive modern endocrinology. London: Academic Press Elsevier; 2019. p. 171-201.Lim Chung Thong Korbonits Márta Korbonits UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS Endocrine Practice 2018 03 473 488 24 5 10.4158/ep-2018-0034Caimari Francisca Korbonits Márta Novel Genetic Causes of Pituitary Adenomas Clinical Cancer Research 2016 10 5030 5042 22 20 10.1158/1078-0432.ccr-16-0452Vasilev Vladimir Daly Adrian F. Zacharieva Sabina Beckers Albert Clinical and Molecular Update on Genetic Causes of Pituitary Adenomas Hormone and Metabolic Research 2020 04 553 561 52 08 10.1055/a-1143-5930Hodson David J. Schaeffer Marie Romanò Nicola Fontanaud Pierre Lafont Chrystel Birkenstock Jerome Molino François Christian Helen Lockey Joe Carmignac Danielle Fernandez-Fuente Marta Le Tissier Paul Mollard Patrice Existence of long-lasting experience-dependent plasticity in endocrine cell networks Nature Communications 2012 01 3 1 10.1038/ncomms1612Mitrofanova L.B., Konovalov P.V., Krylova Yu.S., i dr. Plyurigormonal'nye kletki adenogipofiza. Novye vozmozhnosti optimizatsii molekulyarnoi diagnostiki neiroendokrinnykh opukholei // Molekulyarnaya meditsina. — 2017. — T. 15. — №6. — S. 38-45.Fauquier Teddy Rizzoti Karine Dattani Mehul Lovell-Badge Robin Robinson Iain C. A. F. SOX2-expressing progenitor cells generate all of the major cell types in the adult mouse pituitary gland Proceedings of the National Academy of Sciences 2008 02 2907 2912 105 8 10.1073/pnas.0707886105Moncho-Amor Veronica Chakravarty Probir Galichet Christophe Matheu Ander Lovell-Badge Robin Rizzoti Karine SOX2 is required independently in both stem and differentiated cells for pituitary tumorigenesis in p27 -null mice Proceedings of the National Academy of Sciences 2021 02 118 7 10.1073/pnas.2017115118Agarwal Sunita K. Mateo Carmen M. Marx Stephen J. Rare Germline Mutations in Cyclin-Dependent Kinase Inhibitor Genes in Multiple Endocrine Neoplasia Type 1 and Related States The Journal of Clinical Endocrinology & Metabolism 2009 01 1826 1834 94 5 10.1210/jc.2008-2083Li Chuzhong Xie Weiyan Rosenblum Jared S. Zhou Jianyu Guo Jing Miao Yazhou Shen Yutao Wang Hongyun Gong Lei Li Mingxuan Zhao Sida Cheng Sen Zhu Haibo Jiang Tao Ling Shiying Wang Fei Zhang Hongwei Zhang Mingshan Qu Yanming Zhang Qi Li Guilin Wang Junmei Ma Jun Zhuang Zhengping Zhang Yazhuo Somatic SF3B1 hotspot mutation in prolactinomas Nature Communications 2020 05 11 1 10.1038/s41467-020-16052-8Miao Yazhou Li Chuzhong Guo Jing Wang Hongyun Gong Lei Xie Weiyan Zhang Yazhuo Identification of a novel somatic mutation of POU6F2 by whole‐genome sequencing in prolactinoma Molecular Genetics & Genomic Medicine 2019 11 7 12 10.1002/mgg3.1022Caimari Francisca Korbonits Márta Novel Genetic Causes of Pituitary Adenomas Clinical Cancer Research 2016 10 5030 5042 22 20 10.1158/1078-0432.ccr-16-0452Chen Yiyuan Gao Hua Xie Weiyan Guo Jing Fang Qiuyue Zhao Peng Liu Chunhui Zhu Haibo Wang Zhuang Wang Jichao Gui Songbai Zhang Yazhuo Li Chuzhong Genomic and transcriptomic analysis of pituitary adenomas reveals the impacts of copy number variations on gene expression and clinical prognosis among prolactin-secreting subtype Aging 2020 12 1276 1293 13 1 10.18632/aging.202304Gao Hua Wang Fei Lan Xiaolei Li Chuzhong Feng Jie Bai Jiwei Cao Lei Gui Songbai Hong Lichuan Zhang Yazhuo Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas BMC Cancer 2015 04 15 1 10.1186/s12885-015-1267-0

The authors declare that there are no conflicts of interest present.